Executive Briefing - Roadmap for success in oncology
This article was originally published in Scrip
Since the launch in 1998 of Roche/Genentech's Herceptin (trastuzumab) – the first monoclonal antibody marketed in oncology with administration determined by tumour marker testing – many significant advances have been made in the treatment of cancer. The value of targeted therapies/chemotherapy combinations and the potential of adjuvant therapy (drug treatment following surgery to reduce the risk of cancer recurrence) have been demonstrated in the clinic to improve survival rates, notably in breast, lung and colon cancers. The targeted therapy concept – drug treatments developed to preferentially target those signalling pathways that are disregulated in tumours – contrasts with earlier cancer treatments, such as cytotoxics and immunomodulators, which were based on broad-acting mechanisms. Several targeted molecules have shown efficacy in a wide range of indications, including cancers of the breast, colon, lung, kidney and lymphoma, with important survival benefits observed in some of them.
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.